{"id":383768,"date":"2020-11-18T07:03:41","date_gmt":"2020-11-18T12:03:41","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=383768"},"modified":"2020-11-18T07:03:41","modified_gmt":"2020-11-18T12:03:41","slug":"biolinerx-to-report-third-quarter-2020-results-on-november-23-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/","title":{"rendered":"BioLineRx to Report Third Quarter 2020 Results on November 23, 2020"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p \/>\n<p \/>\n<p>\n        <b><br \/>\n          <i>Management to hold a conference call at 10:00 a.m. <\/i><br \/>\n          <i>EST<\/i><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <span class=\"xn-location\">TEL AVIV, Israel<\/span>, <span class=\"xn-chron\">Nov. 18, 2020<\/span> \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology,\u00a0announced today it will release its unaudited financial results for the quarter ended <span class=\"xn-chron\">September 30, 2020<\/span> on <span class=\"xn-chron\">Monday, November 23, 2020<\/span>, before the US markets open.<\/p>\n<p>The Company will host a conference call on <span class=\"xn-chron\">Monday, November 23, 2020<\/span> at 10:00 a.m. EST\u00a0featuring remarks by <span class=\"xn-person\">Philip Serlin<\/span>, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the <a target=\"_blank\" href=\"https:\/\/ir.biolinerx.com\/events\/event-details\/biolinerx-q3-2020-earnings-conference-call\" rel=\"nofollow noopener noreferrer\">Investor Relations<\/a> page of BioLineRx&#8217;s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. <\/p>\n<p>To dial into the conference call, please dial +1-866-744-5399 from the U.S. or +972-3-918-0664 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the <a target=\"_blank\" href=\"https:\/\/ir.biolinerx.com\/events\/event-details\/biolinerx-q3-2020-earnings-conference-call\" rel=\"nofollow noopener noreferrer\">Investor Relations<\/a> page of BioLineRx&#8217;s website. A dial-in replay of the call will be available until <span class=\"xn-chron\">November 25, 2020<\/span>; please dial +1-877-456-0009 from the U.S. or +972-3-925-5929 internationally.<\/p>\n<p>\n        <b>About BioLineRx<\/b>\n      <\/p>\n<p>BioLineRx Ltd. (NASDAQ\/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company&#8217;s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and\/or commercialization.<\/p>\n<p>The Company&#8217;s lead program, Motixafortide (BL-8040), is a cancer therapy platform currently being evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation. Motixafortide is also being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA<sup>\u00ae<\/sup> and chemotherapy under a collaboration agreement with MSD, as well as a Phase <span class=\"xn-money\">2b<\/span> study in consolidation AML. <\/p>\n<p>BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1\/2a study. <\/p>\n<p>For additional information on BioLineRx, please visit the Company&#8217;s website at <a target=\"_blank\" href=\"http:\/\/www.biolinerx.com\/\" rel=\"nofollow noopener noreferrer\">www.biolinerx.com<\/a>, where you can review the Company&#8217;s SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on <a target=\"_blank\" href=\"https:\/\/www.facebook.com\/BioLineRx-786986118113858\/?fref=ts\" rel=\"nofollow noopener noreferrer\">Facebook<\/a>,\u00a0<a target=\"_blank\" href=\"https:\/\/twitter.com\/BioLineRx_Ltd\" rel=\"nofollow noopener noreferrer\">Twitter<\/a>, and <a target=\"_blank\" href=\"https:\/\/www.linkedin.com\/company\/biolinerx\" rel=\"nofollow noopener noreferrer\">LinkedIn<\/a>.<\/p>\n<p>\n        <b>Contact:\u00a0 <br \/><\/b>Tim McCarthy\u00a0 <br \/>LifeSci Advisors, LLC\u00a0\u00a0 <br \/>+1-212-915-2564\u00a0\u00a0\u00a0 <br \/><a target=\"_blank\" href=\"mailto:tim@lifesciadvisors.com\" rel=\"nofollow noopener noreferrer\">tim@lifesciadvisors.com<\/a>\u00a0 <\/p>\n<p>or<\/p>\n<p>Moran Meir\u00a0\u00a0 <br \/>LifeSci Advisors, LLC\u00a0\u00a0 <br \/>+972-54-476-4945\u00a0\u00a0\u00a0 <br \/><a target=\"_blank\" href=\"mailto:moran@lifesciadvisors.com\" rel=\"nofollow noopener noreferrer\">moran@lifesciadvisors.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN96149&amp;sd=2020-11-18\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020-301175789.html\">http:\/\/www.prnewswire.com\/news-releases\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020-301175789.html<\/a><\/p>\n<p>SOURCE  BioLineRx Ltd.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LN96149&amp;Transmission_Id=202011180700PR_NEWS_USPR_____LN96149&amp;DateId=20201118\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, Nov. 18, 2020 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology,\u00a0announced today it will release its unaudited financial results for the quarter ended September 30, 2020 on Monday, November 23, 2020, before the US markets open. The Company will host a conference call on Monday, November 23, 2020 at 10:00 a.m. EST\u00a0featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx&#8217;s website. Please allow extra time prior to the call to visit the site and download any necessary software to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioLineRx to Report Third Quarter 2020 Results on November 23, 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-383768","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioLineRx to Report Third Quarter 2020 Results on November 23, 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioLineRx to Report Third Quarter 2020 Results on November 23, 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, Nov. 18, 2020 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology,\u00a0announced today it will release its unaudited financial results for the quarter ended September 30, 2020 on Monday, November 23, 2020, before the US markets open. The Company will host a conference call on Monday, November 23, 2020 at 10:00 a.m. EST\u00a0featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx&#8217;s website. Please allow extra time prior to the call to visit the site and download any necessary software to &hellip; Continue reading &quot;BioLineRx to Report Third Quarter 2020 Results on November 23, 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-18T12:03:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN96149&amp;sd=2020-11-18\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioLineRx to Report Third Quarter 2020 Results on November 23, 2020\",\"datePublished\":\"2020-11-18T12:03:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/\"},\"wordCount\":410,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN96149&amp;sd=2020-11-18\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/\",\"name\":\"BioLineRx to Report Third Quarter 2020 Results on November 23, 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN96149&amp;sd=2020-11-18\",\"datePublished\":\"2020-11-18T12:03:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN96149&amp;sd=2020-11-18\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LN96149&amp;sd=2020-11-18\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioLineRx to Report Third Quarter 2020 Results on November 23, 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioLineRx to Report Third Quarter 2020 Results on November 23, 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/","og_locale":"en_US","og_type":"article","og_title":"BioLineRx to Report Third Quarter 2020 Results on November 23, 2020 - Market Newsdesk","og_description":"PR Newswire Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, Nov. 18, 2020 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology,\u00a0announced today it will release its unaudited financial results for the quarter ended September 30, 2020 on Monday, November 23, 2020, before the US markets open. The Company will host a conference call on Monday, November 23, 2020 at 10:00 a.m. EST\u00a0featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx&#8217;s website. Please allow extra time prior to the call to visit the site and download any necessary software to &hellip; Continue reading \"BioLineRx to Report Third Quarter 2020 Results on November 23, 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-18T12:03:41+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN96149&amp;sd=2020-11-18","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioLineRx to Report Third Quarter 2020 Results on November 23, 2020","datePublished":"2020-11-18T12:03:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/"},"wordCount":410,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN96149&amp;sd=2020-11-18","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/","name":"BioLineRx to Report Third Quarter 2020 Results on November 23, 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN96149&amp;sd=2020-11-18","datePublished":"2020-11-18T12:03:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN96149&amp;sd=2020-11-18","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN96149&amp;sd=2020-11-18"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioLineRx to Report Third Quarter 2020 Results on November 23, 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=383768"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383768\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=383768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=383768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=383768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}